In data presented at 2017 ASH, a highly selective inhibitor of KIT D816V is showing promise for advanced systemic mastocytosis, a hard-to-treat group of poor prognosis mast cell neoplasms.
At the 2017 ASH annual meeting, investigators presented data on the pharmacodynamic effects of copanlisib in patients with NHL and solid tumors that showed dose-dependent on-target activity with the drug.
Researchers presented data at the 2017 ASH annual meeting about their new personalized MDS prediction model that uses clinical and genomic data to help better guide therapy and improve outcomes compared with other models.
ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.
On April 28, 2017, the US Food and Drug Administration approved midostaurin (Rydapt) for treating newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis.
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.
CD38 expression was associated with response to daratumumab monotherapy in patients with multiple myeloma.
A study testing the all oral combination of ixazomib, cyclophosphamide, and dexamethasone showed that patients with newly diagnosed multiple myeloma responded well to the experimental treatment regimen.
The US Food and Drug Administration (FDA) has approved the type 2 anti-CD20 monoclonal antibody obinutuzumab (Gazyva) for patients with follicular lymphoma, a common type of non-Hodgkin lymphoma.